High-density lipoprotein cholesterol and the risk of nephropathy in type 2 diabetic patients

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 8, 2013, Pages 751-757

  Chang, Y H ^a   Chang, D M ^a   Lin, K C ^a   Hsieh, C H ^b   Lee, Y J ^a  

^a Lee's Endocrinology Clinic   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Diabetic nephropathy; High density lipoprotein cholesterol; Type 2 diabetes mellitus

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

DIABETIC NEPHROPATHY; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; TYPE 2 DIABETES MELLITUS;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84880037227     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.05.005     Document Type: Article

References (30)

1. Targher G., Zoppini G., Chonchol M., Negri C., Stoico V., Perrone F., et al. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr Metab Cardiovasc Dis 2011, 21:294-301.
2. Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl. 1):S11-S61.
3. Tu S.T., Chang S.J., Chen J.F., Tien K.J., Hsiao J.Y., Chen H.C., et al. Prevention of diabetic nephropathy by tight target control in an Asian population with type 2 diabetes mellitus: a 4-year prospective analysis. Arch Intern Med 2010, 170:155-161.
4. Yu N.C., Su H.Y., Tsai S.T., Lin B.J., Shiu R.S., Hsieh Y.C., et al. ABC control of diabetes: survey data from national diabetes health promotion centers in Taiwan. Diabetes Res Clin Pract 2009, 84:194-200.
5. Kilpatrick E.S., Rigby A.S., Atkin S.L. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the diabetes control and complications trial. Diabetes Care 2008, 31:2198-2202.
6. Nalysnyk L., Hernandez-Medina M., Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010, 12:288-298.
7. Kilpatrick E.S., Rigby A.S., Atkin S.L. The role of blood pressure variability in the development of nephropathy in type 1 diabetes. Diabetes Care 2010, 33:2442-2447.
8. Di Flaviani A., Picconi F., Di Stefano P., Giordani I., Malandrucco I., Maggio P., et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care 2011, 34:1605-1609.
9. Tolonen N., Forsblom C., Thorn L., Waden J., Rosengard-Barlund M., Saraheimo M., et al. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia 2009, 52:2522-2530.
10. Zoppini G., Targher G., Chonchol M., Perrone F., Lippi G., Muggeo M. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2009, 19:580-586.
11. Wang C.P., Hsu H.L., Hung W.C., Yu T.H., Chen Y.H., Chiu C.A., et al. Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clin Endocrinol (Oxf) 2009, 70:876-882.
12. Wang C.P., Hung W.C., Yu T.H., Hsu H.L., Chen Y.H., Chiu C.A., et al. Brachial-ankle pulse wave velocity as an early indicator of left ventricular diastolic function among hypertensive subjects. Clin Exp Hypertens 2009, 31:31-43.
13. Chang Y.H., Chang D.M., Lin K.C., Shin S.J., Lee Y.J. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011, 27:515-527.
14. Adler A.I. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
15. Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., Billot L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
16. Ma J., Yang W., Fang N., Zhu W., Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutr Metab Cardiovasc Dis 2009, 19:596-603.
17. Kilpatrick E.S., Rigby A.S., Atkin S.L. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 2009, 32:1901-1903.
18. Okada H., Fukui M., Tanaka M., Inada S., Mineoka Y., Nakanishi N., et al. Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes. Atherosclerosis 2012, 220:155-159.
19. Salardi S., Balsamo C., Zucchini S., Maltoni G., Scipione M., Rollo A., et al. High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type 1 diabetes treated or not with enalapril: the influence of HDL cholesterol. Diabetes Care 2011, 34:424-429.
20. Vaziri N.D. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. J Ren Nutr 2010, 20:S35-S43.
21. Zhou H., Tan K.C., Shiu S.W., Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transplant 2008, 23:927-933.
22. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000, 43:312-320.
23. Demacker P.N., Schade R.W., Jansen R.T., Van't Laar A. Intra-individual variation of serum cholesterol, triglycerides and high density lipoprotein cholesterol in normal humans. Atherosclerosis 1982, 45:259-266.
24. Bookstein L., Gidding S.S., Donovan M., Smith F.A. Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Impact on the assessment of risk according to the national cholesterol education program guidelines. Arch Intern Med 1990, 150:1653-1657.
25. Tsalamandris C., Panagiotopoulos S., Allen T.J., Waldrip L., Van Gaal B., Goodall I., et al. Long-term intraindividual variability of serum lipids in patients with type I and type II diabetes. J Diabet Complications 1998, 12:208-214.
26. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
27. Cushman W.C., Evans G.W., Byington R.P., Goff D.C., Grimm R.H., Cutler J.A., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
28. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
29. Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
30. Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., Koprowicz K., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.